Feature | February 10, 2014

Inflammation Testing May Predict Cardiac Risk in Corporate Wellness Programs

February 10, 2014 — Traditional fingerstick screening for glucose and lipids is proving inadequate when identifying near-term cardiovascular risk in employed populations, according to Jake Orville, CEO of Cleveland HeartLab (CHL). This position is supported by data from the American Heart Association. AHA reported 50 percent of all heart attacks and strokes occur in individuals with normal cholesterol and — for approximately 30 percent of patients with cardiovascular disease — their first sign of disease is death.
 
Orville is scheduled to present "The Role of Inflammation Testing in Corporate Wellness Programs" at the 2014 Health & Wellness Congress, Feb. 27-28. The conference, held at the Monte Carlo Resort and Casino in Las Vegas, will bring together leading corporate wellness experts to discuss emerging trends and strategies that promote well-being at the worksite.
 
"Inflammation testing provides reassurance on another important level," Orville said. "In addition to detecting employees with possible hidden risk, we are also able to provide positive feedback for those employees who are already leading healthy lifestyles. Knowing that their health habits are decreasing the inflammation in their blood vessels and their risk of an event can be a powerful incentive for people to stick with positive lifestyle changes."
 
Cleveland HeartLab is a provider of onsite testing for corporate wellness programs. A clinical laboratory and cardiovascular disease management provider, CHL offers a multi-marker approach — adding inflammation-specific blood tests to the traditional screening panel — to identify employees may go undetected. CHL's inflammatory biomarkers deliver insight into cardiovascular disease risk such as "vulnerable plaque" that may rupture into the vessel and block blood flow, leading to heart attack or stroke.
 
Orville will present both the science of inflammation testing and the results of corporate wellness programs that have adopted inflammation testing for risk stratification and targeted intervention. With new mandates from the Affordable Care Act for companies to provide screening programs to employees, obtaining the greatest efficacy as well as return on investment becomes paramount.
 
For more information: www.clevelandheartlab.com

Related Content

LimFlow System, critical limb ischemia, CLI, CE Mark
News | Stents Peripheral| December 08, 2016
LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for...
Corsens Medical, Corsens Cardiac Monitor, FDA 510(k) clearance
Technology | Patient Monitors| December 08, 2016
Corsens Medical Ltd. announced that it has received clearance for a Pre-Marketing Notification (510(k)) with the U.S....
Sponsored Content | Videos | Angiography| December 07, 2016
Shimadzu's latest generation interventional lab angiography imaging system, the Trinias, enables advanced imaging cap
Lotus Edge valve
News | Heart Valve Technology| December 07, 2016
December 7, 2016 — Boston Scientific announced a definitive agreement to acquire certain manufacturing assets and cap
INRatio, Alere, Abbott, I and R testing, INR testing
Feature | Point of Care Testing| December 07, 2016
December 7, 2016 — Abbott has filed a complaint to terminate its proposed acquisition of Alere based on the substanti
Impella CP, Abiomed
News | Hemodynamic Support Devices| December 07, 2016
December 7, 2016 — Abiomed Inc. announced it has expanded its U.S.
Vascular Solutions, Teleflex
Feature | December 07, 2016
December 7, 2016 — Teleflex Inc. and Vascular Solutions Inc.
Siemens Healthineers, PURE Platform, angiography, EVAR, CTO, RSNA 2016
News | Angiography| December 07, 2016
December 7, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (
Spectranetics, Stellarex 0.014-inch DCB, CE Mark
News | Drug-Eluting Balloons| December 06, 2016
December 6, 2016 — The Spectranetics Corp.
TCT 2016, TCT.16, main arena, late breaking trials, transcatheter cardiovascular therapeutics

There were several hot topics that came out of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting Oct. 29 - Nov. 2, which made this month's top 20 list, including several videos. Number 4 on the list of content was the result of the EXCEL Trial key TCT late-breaker, which showed stenting is equal in outcomes to surgery for the first time, when using one of the latest generation drug-eluting stents. 

Feature | December 05, 2016
December 5, 2016 — Here is the list of the top 20 most popular pieces of content on the Diagnostic and Interventional
Overlay Init